Matching articles for "RSV"
Issue 1754 · May 11, 2026 Free
In Brief: RSV Vaccine (Arexvy) for Ages 18-49

The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and…

Med Lett Drugs Ther. 2026 May 11; 68(1754):77-8 doi:10.58347/tml.2026.1754d
The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and mResvia , are now all licensed for prevention of RSV lower respiratory tract disease in persons ≥60 years old and in those 18-59 years old who are at increased risk of lower respiratory tract disease caused by RSV. Abrysvo is also licensed for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated lower respiratory tract disease in their infants from birth to 6 months.
Issue 1738 · September 29, 2025 Free
Influenza Vaccines for 2025-2026

Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed…

Med Lett Drugs Ther. 2025 Sep 29; 67(1738):153-8 doi:10.58347/tml.2025.1738a
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Issue 1735 · August 18, 2025
Clesrovimab (Enflonsia) for Prevention of Severe RSV Infection in Infants

The FDA has approved clesrovimab-cfor ( Enflonsia – Merck), a long-acting monoclonal antibody, for prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and…

Med Lett Drugs Ther. 2025 Aug 18; 67(1735):129-31 doi:10.58347/tml.2025.1735a
The FDA has approved clesrovimab-cfor ( Enflonsia – Merck), a long-acting monoclonal antibody, for prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants born during or entering their first RSV season. Clesrovimab is the second drug to be approved for this indication; nirsevimab (Beyfortus) , another long-acting monoclonal antibody, was the first. Palivizumab (Synagis) , a shorter-acting antibody, is FDA-approved for prevention of severe RSV LRTI in certain high-risk children ≤24 months old.
Issue 1722 · February 17, 2025 Free
In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo

The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):31-2 doi:10.58347/tml.2025.1722d
The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within 42 days of administration of either vaccine. Both vaccines are FDA-approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants from birth through 6 months of age.
Issue 1713 · October 14, 2024 Free
A New RSV Vaccine (mResvia) for Adults ≥60 Years Old

TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):166-8 doi:10.58347/tml.2024.1713d
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, Arexvy and Abrysvo , are also available for prevention of RSV LRTD. Arexvy is approved for use in adults ≥50 years old. Abrysvo is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.
Issue 1711 · September 16, 2024 Free
Influenza Vaccine for 2024-2025

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):145-50 doi:10.58347/tml.2024.1711a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Issue 1710 · September 2, 2024
Drugs for COPD

The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD…

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):137-44 doi:10.58347/tml.2024.1710a
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Issue 1707 · July 22, 2024 Free
In Brief: RSV Vaccine (Arexvy) for Ages 50-59

The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD)…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):113-4 doi:10.58347/tml.2024.1707a
The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old. Two other RSV vaccines have received FDA approval: Abrysvo , a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants, and mResvia , an mRNA vaccine recently licensed for use in adults ≥60 years old that will be available for the 2024-25 RSV season.
Issue 1687 · October 16, 2023 Free
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024

New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and that more closely target currently circulating variants have been licensed by the FDA for use in persons…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):167-8 doi:10.58347/tml.2023.1687c
New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and that more closely target currently circulating variants have been licensed by the FDA for use in persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old. The bivalent (original and Omicron BA.4/5) formulations of the Pfizer and Moderna vaccines are no longer authorized for use in the US.
Issue 1686 · October 2, 2023
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease

Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60…

Med Lett Drugs Ther. 2023 Oct 2; 65(1686):153-6 doi:10.58347/tml.2023.1686a
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
Issue 1685 · September 18, 2023
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children

The FDA has approved nirsevimab-alip ( Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates…

Med Lett Drugs Ther. 2023 Sep 18; 65(1685):145-7 doi:10.58347/tml.2023.1685a
The FDA has approved nirsevimab-alip ( Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.
Issue 127 · March 1, 2013
Antiviral Drugs

The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been…

Treat Guidel Med Lett. 2013 Mar; 11(127):19-30
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Issue 98 · October 1, 2010
Drugs for Non-HIV Viral Infections

The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by…

Treat Guidel Med Lett. 2010 Oct; 8(98):71-82
The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed in another issue of Treatment Guidelines .
Issue 59 · July 1, 2007
Drugs for Non-HIV Viral Infections

The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA.…

Treat Guidel Med Lett. 2007 Jul; 5(59):59-70
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used in the prevention of viral infections are discussed in the " Adult Immunization " issue of Treatment Guidelines .
Issue 32 · April 1, 2005
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the…

Treat Guidel Med Lett. 2005 Apr; 3(32):23-32
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the FDA.
Issue 13 · September 1, 2003
Drugs for Pneumonia

The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid…

Treat Guidel Med Lett. 2003 Sep; 1(13):83-8
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Issue 1123 · February 4, 2002
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some…

Med Lett Drugs Ther. 2002 Feb 4; 44(1123):9-16
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some new recommendations for old drugs have been added.
Issue 1098 · February 19, 2001
Synagis Revisited

Palivizumab ( Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and children.

Med Lett Drugs Ther. 2001 Feb 19; 43(1098):13-4
Palivizumab ( Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and children.
Issue 1067 · December 3, 1999
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.

Med Lett Drugs Ther. 1999 Dec 3; 41(1067):113-20
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.
Issue 1006 · August 1, 1997
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.

Med Lett Drugs Ther. 1997 Aug 1; 39(1006):69-76
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.